One-Handed Advantage Vascugenix's Speed-Torque device enables one-handed guidewire manipulation during PCI and PVI, shortening procedure times and reducing radiation exposure. With FDA clearance, it is positioned for rapid adoption in cath labs focused on patient safety and workflow efficiency. Target hospitals and procedure suites with a clear ROI narrative.

Validation via Partnership The Baptist Health partnership demonstrates real-world deployment and market entry potential within health systems. Use this reference to approach other cardiology and interventional programs for pilots and broader rollout, leveraging the success story to shorten procurement cycles.

Market Focus Primary opportunity lies in interventional cardiology and peripheral interventions where guidewire control is critical; align messaging to surgical teams about reducing radiation and procedure time. Leverage GPOs and specialized distributors to scale reach given the small internal team.

Growth Funding Current revenue runway is modest and funding is limited; seek strategic investors, grants, or partnerships with larger device firms to accelerate manufacturing, distribution, and field service. Collaboration with larger OEMs could unlock co-development and rapid market access.

Competitive Position The device's patented design offers a differentiator against larger incumbents by focusing on one-handed control and safety; pursue clinical pilots and case studies to build differentiating evidence. Explore expansion to related interventional platforms and regulatory clearance in additional markets to widen addressable market.